# Alzheimer's, Parkinson's & Neurodegeneration: State of the Field (October 2026)

Research dossier · v1 · updated 2026-10-30 · 4,039 words · 49 sources · 30 claims · verification: verified

This dossier covers anti-amyloid antibodies, plasma p-tau217 diagnostics, alpha-synuclein seed amplification and antisense therapy for ALS. The main takeaway is that blood tests now approach CSF accuracy in specialist cohorts, while the size of antibody benefit, its safety trade-offs and its cost of access remain contested.

## Contents

- Executive summary
- Background and core concepts
- Timeline of key milestones
- State of the art
  - Anti-amyloid antibodies
  - Blood biomarkers for amyloid and tau
  - Alpha-synuclein seed amplification and Parkinson's disease
  - ALS and presymptomatic SOD1 therapy
  - Preclinical and prevention studies
  - Quantitative benchmarks
- Open problems and active debates
- Major programs and players
- Outlook: what to watch (next 12-18 months)
- Key papers
- Glossary

## Sample findings

- The core CLARITY AD lecanemab study randomized 1,795 participants; across core and extension, ARIA-E was reported in 13.6% and ARIA-H in 16.0% of lecanemab recipients.
- A pooled analysis of six randomized trials (4,471 patients) found a statistically significant CDR-SB benefit (P = 0.01) and higher ARIA-E and ARIA-H risk than placebo for FDA-approved anti-amyloid antibodies.

## Get the full dossier

GET https://space-kitty.com/api/v1/dossiers/neurodegeneration costs $0.20 via x402 (USDC on Base Sepolia (testnet)). Send `Accept: text/markdown` for Markdown or `application/json` for structured data (claims with citations, timeline, benchmarks, open problems, glossary, bibliography).
---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.